δ-阿片受体激动剂调控慢性青光眼大鼠模型I类和IIb类HDAC的变化
该研究在大鼠慢性高眼压模型中观察δ-阿片受体激动剂SNC-121对I类和IIb类组蛋白去乙酰化酶(HDAC)的调控及视网膜神经节细胞(RGC)保护作用。高眼压动物视觉功能下降且HDAC活性及表达升高,SNC-121治疗可改善视觉功能并阻断HDAC上调。结果提示早期δ-阿片受体激活通过抑制HDAC发挥RGC神经保护作用。
要点
- 高眼压大鼠视觉 acuity、对比敏感度和模式ERG下降,SNC-121治疗显著改善。
- 高眼压动物伤后7天和42天I类和IIb类HDAC活性显著升高。
- SNC-121在7天和42天阻断HDAC活性、mRNA和蛋白表达的上调。
核心结论
- I类和IIb类HDAC在青光眼早期被激活并上调。
- 早期δ-阿片受体激活可持久抑制I类和IIb类HDAC活性和表达,可能部分参与RGC神经保护。
研究设计与样本
- 大鼠眼内注射2M高渗盐水至角膜缘静脉升高眼压建立慢性青光眼模型。
- SNC-121(1 mg/kg;腹腔注射)给药7天。
- 伤后7天和42天取视网膜,用酶法、qRT-PCR、Western blotting和免疫组化检测HDAC活性、mRNA和蛋白表达。
主要发现
- 高眼压动物视觉 acuity、对比敏感度和模式ERG下降,SNC-121治疗显著改善。
- 伤后7天高眼压动物I类和IIb类HDAC活性显著升高。
- 伤后7天HDAC1 mRNA增加1.33 ± 0.07倍、蛋白增加20.2 ± 2.7%,HDAC2 mRNA增加1.4 ± 0.05倍、蛋白增加17.0 ± 2.4%,HDAC3 mRNA增加1.4 ± 0.06倍、蛋白增加17.4 ± 3.4%,HDAC6 mRNA增加1.5 ± 0.09倍、蛋白增加15.1 ± 3.3%。
- 伤后42天高眼压动物HDAC mRNA和蛋白表达进一步升高。
- SNC-121在伤后7天和42天阻断高眼压动物HDAC活性、mRNA和蛋白表达的上调。
临床怎么用
- 在青光眼模型中,早期干预δ-阿片受体可抑制I类和IIb类HDAC的活性和表达上调。
- SNC-121治疗与视觉功能改善相关,提示靶向HDAC的表观遗传调控可能成为青光眼神经保护策略。
局限性
- 研究为大鼠模型,结果向临床转化需进一步验证。
- 原文未报告样本量、P值及置信区间等统计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study determines if δ-opioid receptor agonist (i.e. SNC-121)-induced epigenetic changes via regulation of histone deacetylases (HDACs) for retinal ganglion cell (RGC) neuroprotection in glaucoma model. METHODS: Intraocular pressure was raised in rat eyes by injecting 2M hypertonic saline into the limbal veins. SNC-121 (1 mg/kg; i.p.) was administered to the animals for 7 days. Retinas were collected at days 7 and 42, post-injury followed by measurement of HDAC activities, mRNA, and protein expression by enzyme assay, quantitative real-time PCR (qRT-PCR), Western blotting, and immunohistochemistry. RESULTS: The visual acuity, contrast sensitivity, and pattern electroretinograms (ERGs) were declined in ocular hypertensive animals, which were significantly improved by SNC-121 treatment. Class I and IIb HDACs activities were significantly increased at days 7 and 42 in ocular hypertensive animals. The mRNA and protein expression of HDAC 1 was increased by 1.33 ± 0.07-fold and 20.2 ± 2.7%, HDAC 2 by 1.4 ± 0.05-fold and 17.0 ± 2.4%, HDAC 3 by 1.4 ± 0.06-fold and 17.4 ± 3.4%, and HDAC 6 by 1.5 ± 0.09-fold and 15.1 ± 3.3% at day 7, post-injury. Both the mRNA and protein expression of HDACs were potentiated further at day 42 in ocular hypertensive animals. HDAC activities, mRNA, and protein expression were blocked by SNC-121 treatment at days 7 and 42 in ocular hypertensive animals. CONCLUSIONS: Data suggests that class I and IIb HDACs are activated and upregulated during early stages of glaucoma. Early intervention with δ-opioid receptor activation resulted in the prolonged suppression of class I and IIb HDACs activities and expression, which may, in part, play a crucial role in RGC neuroprotection.
引用
- Zaidi SAH, Guzman W, Singh S, et al. Changes in Class I and IIb HDACs by δ-Opioid in Chronic Rat Glaucoma Model. Invest Ophthalmol Vis Sci. 2020. PMID: 33263714. doi:10.1167/iovs.61.14.4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。